Nesiritide For Decompensated Congestive Heart Failure
Nesiritide, a recombinant human B-type natriuretic peptide (BNP), has been approved by the FDA of intravenous (IV) treatment of patients with decompensated congestive heart failure who have dyspnea at rest or with minimal exertion (New York Heart Association class IV)....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Nesiritide For Decompensated Congestive Heart Failure
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1118
Article Code: 1118b
Date: November 12, 2001
Volume: 43
Pages: 100-101
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1118
Article Code: 1118b
Date: November 12, 2001
Volume: 43
Pages: 100-101
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)
